OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	92
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	63
Long-acting preexposure prophylaxis: early data on roll-out in the United States	40
Humoral immunity in HIV-1 post-treatment controllers	38
Future options for long-acting HIV treatment and prevention	28
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	26
Assessing proviral competence: current approaches to evaluate HIV-1 persistence	26
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	25
Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine	24
Technologies for HIV-1 drug resistance testing: inventory and needs	22
Bridging the gaps in perinatal HIV: treatment and prevention	21
Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children	19
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	19
Preventing perinatal HIV acquisition; current gaps and future perspectives	19
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	18
Editorial introductions	17
Elite controllers microbiome: unraveling the mystery of association and causation	17
Editorial introductions	17
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	17
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	16
HIV cure: an acceptability scientific agenda	16
Humanized mice for studying HIV latency and potentially its eradication	16
Editorial: New drugs for HIV: quo vadis?	14
Editorial: Immune-mediated control of HIV	14
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	14

Host factors predisposing to kidney disease in people with HIV	14
The severity of COVID-19 across the spectrum of HIV	13
Is an HIV vaccine still achievable?	13
Pediatric perspective: the microbiome in vertical HIV-infection: unravelling gaps, challenges, and therapeutic potential	12
HIV and cardiovascular disease: the role of inflammation	11
Exosomes in HIV infection	11
The sounds of silencing: dynamic epigenetic control of HIV latency	11
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	11
The changing use and program costs of HIV-related laboratory testing over 20 years in an HIV cohort	10
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	10
Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection	10
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	10
HIV drug resistance in various body compartments	10
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	10
Delivery platforms for broadly neutralizing antibodies	9
“Block and lock” viral integration sites in persons with drug-free control of HIV-1 infection	8
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors	8
Editorial introduction	8
Harnessing natural killer cells to target HIV-1 persistence	8
Strategies to target the central nervous system HIV reservoir	8
Editorial introduction	7
What's in a cure: designing a broad-spectrum HIV gene therapy	7
Editorial introduction	7
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	7
Polyfunctionality of broadly neutralizing HIV-1 antibodies	6
Editorial introductions	6
Editorial introductions	6
Soluble markers of viral rebound and post-treatment HIV control	5
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	5
Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy	5
Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95–95–95 target	5
Advances in the mathematical modeling of posttreatment control of HIV-1	5
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’	5
The rectal microbiome: understanding its role in HIV transmission	5
Editorial introduction	5
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	5
Long-acting antiretroviral therapy in the context of viral suppression	5
Anticipating HIV viral escape – resistance to active and passive immunization	5
Causes and outcomes of hepatic fibrosis in persons living with HIV	5
Intersections between HIV and obesity in emerging economies	5